Akoya Biosciences And NeraCare Sign Exclusive Global License Agreement To Develop And Commercialize Immunoprint Test For Early-Stage Melanoma Treatment Decisions, Leveraging Akoya's PhenoImager HT Platform To Address High-Risk Relapse Patients With...

BenzingaDec 10 21:16

Express News | Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

BreakingsDec 10 21:15

Akoya Biosciences and NeraCare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

GlobeNewswireDec 10 21:15

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

GlobeNewswireDec 9 21:00

Not Many Are Piling Into Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Yet As It Plummets 33%

Simply Wall StDec 6 18:20

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

PR NewswireDec 2 23:18